• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical & developmental immunology. >Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer
【24h】

Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer

机译：Th1细胞因子分泌重组重组 italic>牛分枝杆菌芽孢杆菌Calmette-Guérin及其在膀胱癌免疫治疗中的前瞻性应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intravesical instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used for treating bladder cancer for 3 decades. However, BCG therapy is ineffective in approximately 30–40% of cases. Since evidence supports the T helper type 1 (Th1) response to be essential in BCG-induced tumor destruction, studies have focused on enhancing BCG induction of Th1 immune responses. Although BCG in combination with Th1 cytokines (e.g., interferon- α ) has demonstrated improved efficacy, combination therapy requires multiple applications and a large quantity of cytokines. On the other hand, genetic manipulation of BCG to secrete Th1 cytokines continues to be pursued with considerable interest. To date, a number of recombinant BCG (rBCG) strains capable of secreting functional Th1 cytokines have been developed and demonstrated to be superior to BCG. This paper discusses current rBCG research, concerns, and future directions with an intention to inspire the development of this very promising immunotherapeutic modality for bladder cancer.
机译：牛分枝杆菌Calmette-Guérin（BCG）的膀胱内滴注已用于治疗膀胱癌已有3年了。但是，BCG治疗在大约30–40％的病例中无效。由于证据支持T辅助1型（Th1）应答在BCG诱导的肿瘤破坏中必不可少，因此研究集中在增强BCG诱导的Th1免疫应答。尽管BCG与Th1细胞因子（例如干扰素-α）联合使用已显示出改善的疗效，但联合治疗需要多次应用和大量细胞因子。另一方面，对卡介苗分泌Th1细胞因子的基因操纵仍在继续引起人们的极大兴趣。迄今为止，已经开发了许多能够分泌功能性Th1细胞因子的重组BCG（rBCG）菌株，并证明其优于BCG。本文讨论了当前的rBCG研究，关注点和未来方向，以期激发这种非常有前途的膀胱癌免疫治疗方法的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号